Abstract
A prospective, multicenter, cohort study from Italy from December 2016 to December 2018. For 287 patients with chronic limb-threatening ischemia (CLTI) who underwent open, endovascular, or hybrid lower extremity revascularization, the 30-day major adverse cardiovascular and major adverse limb events (MALE) rates were 3% and 2%, respectively. At 1 year, the overall survival, amputation-free survival, freedom from MALE, and primary patency rate was 89%, 87%, 63%, and 71%, respectively. Smoking, renal failure, Rutherford class ≥5, and below-the-knee arterial disease were significant predictors of amputation after multivariate analysis. Iloprost infusion was a significant protective factor against MALE, and cilostazol was a significant protective factor against restenosis. Medical treatment, including statins, cilostazol, and iloprost, were associated with improved 1-year freedom from restenosis and amputation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
